Optimal Therapy for Patients with Hepatocellular Carcinoma and Resistance or Intolerance to Sorafenib: Challenges and SolutionsDecember 08, 2017
[Journal of Hepatocellular Carcinoma] This research examines systemic therapies that can be considered in patients with sorafenib refractory hepatocellular carcinoma.
Reducing the initial dose of sorafenib was shown to have some benefits — such as reduced pill burden, lower costs, and decreased AE-related discontinuation rates — and OS was noninferior compared with the standard dose in patients with hepatocellular carcinoma.
Comparative Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysisJuly 07, 2016
[Oncotargets and Therapy] This research evaluates the comparative efficacy and safety of axitinib and sorafenib for the treatment of metastatic renal cell carcinoma.
Liver tumor cells do not respond to sorafenib if they have a less differentiated phenotype, known as the mesenchymal type, and express CD44, according to a new study.
When tumor stops responding to U.S. Food and Drug Administration approval for the anti-cancer drug sorafenib (Nexavar) has been expanded to include late-stage differentiated thyroid cancer, the most common type of thyroid cancer.
The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay nearly twice as long as placebo, according to the results of the randomized phase III trial known as DECISION.
Sorafenib improves survival in patients whose cancer is resistant to radioactive iodine treatment.
An increased risk of coronary artery stenosis in cancer survivors may be a long-term posttreatment effect of chest radiotherapy.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|